Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients.

ABSTRACT:

Purpose

This prospective clinical trial investigated sodium (²³Na) MRI at 7 Tesla (T) field strength as biomarker for tumor extent, isocitrate dehydrogenase (IDH) mutation and O6-methylguanine DNA methyltransferase (MGMT) promotor methylation in glioma patients.

Methods

28 glioma patients underwent ²³Na MRI on a 7T scanner (Siemens Healthcare, Erlangen, Germany) parallel to standard 3T MRI before chemoradiation. Areas of Gadolinium-contrast enhancement (gdce), non-enhancing T2-hyperintensity (regarded as edema), necrosis, and normal-appearing white matter (nawm) were segmented on 3T MRI imaging and were co-registered with the ²³Na images. The median total ²³Na concentrations of all areas were compared by pairwise t-tests. Furthermo

SUBMITTER: Regnery S 

PROVIDER: S-EPMC7527584 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature